Pfizer Aktie
WKN: 852009 / ISIN: US7170811035
|
30.05.2025 14:46:37
|
Pfizer's BRAFTOVI Combo Cuts Risk Of Death By Half For BRAF V600E-mutant Colorectal Cancer Patients
(RTTNews) - Pfizer Inc. (PFE) Friday said its BRAFTOVI in combination with cetuximab and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) reduced the risk death by half in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation.
A second interim analysis of the Phase 3 BREAKWATER study showed that BRAFTOVI combo reduced the risk of death by 51% compared to standard-of-care chemotherapy with or without bevacizumab.
In the primary analysis of progression-free survival (PFS), the BRAFTOVI combination regimen reduced the risk of disease progression or death by 47%.
These data will be presented today at the 2025 American Society of Clinical Oncology Annual Meeting and have been simultaneously published in the New England Journal of Medicine.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Pfizer Inc.mehr Nachrichten
Analysen zu Pfizer Inc.mehr Analysen
| 09:13 | Pfizer Neutral | JP Morgan Chase & Co. | |
| 24.09.25 | Pfizer Buy | Jefferies & Company Inc. | |
| 22.09.25 | Pfizer Neutral | JP Morgan Chase & Co. | |
| 17.09.25 | Pfizer Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 06.08.25 | Pfizer Kaufen | DZ BANK |
Aktien in diesem Artikel
| Pfizer Inc. | 21,67 | 6,72% |
|
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.